The estimated Net Worth of Biotechnology Fund Fcpr is at least $413 Thousand dollars as of 7 May 2014. Biotechnology Fcpr owns over 50,000 units of Scynexis Inc stock worth over $413,108 and over the last 11 years Biotechnology sold SCYX stock worth over $0.
Biotechnology has made over 1 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Biotechnology bought 50,000 units of SCYX stock worth $500,000 on 7 May 2014.
The largest trade Biotechnology's ever made was buying 50,000 units of Scynexis Inc stock on 7 May 2014 worth over $500,000. On average, Biotechnology trades about 50,000 units every 0 days since 2014. As of 7 May 2014 Biotechnology still owns at least 295,077 units of Scynexis Inc stock.
You can see the complete history of Biotechnology Fcpr stock trades at the bottom of the page.
Biotechnology's mailing address filed with the SEC is 57 RUE DE RICHELIEU, , PARIS, I0, 75002.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, and Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: